Miromatrix CEO Jeff Ross to Present at the Bioregate European Regenerative Medicine Forum
EDEN PRAIRIE, Minn., Sept. 20, 2022 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced CEO Jeff Ross will present at the Bioregate European Regenerative Medicine Forum. The conference, held this year on September 21-23 in Louvain-la-Neuve, Belgium, is dedicated to the 4R Medicine, Repair, Replacement, Regeneration, and Reprogramming.
Related news for (MIRO)
- United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
- Miromatrix to Report First Quarter 2023 Financial Results
- Miromatrix to Report First Quarter 2023 Financial Results
- CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
- CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation